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OBJECTIVES: Serotonin plays a central role in ejaculation and selective serotonin reuptake inhibitors have been
successfully used to treat premature ejaculation. Here, we evaluated the relationship between a polymorphism
in the serotonin transporter gene-linked polymorphic region (5-HTTLPR) and the response of patients with
premature ejaculation to SSRI medication.
METHODS: Sixty-nine premature ejaculation patients were treated with 20 mg/d paroxetine for three months.
The Intravaginal Ejaculatory Latency Time and International Index of Erectile Function scores were compared
with baseline values. The patients were scored as having responded to therapy when a 2-fold or greater
increase was observed in Intravaginal Ejaculatory Latency Time compared with baseline values after three
months. Three genotypes of 5-HTTLPR were studied: LL, LS and SS. The appropriateness of the allele frequencies
in 5-HTTLPR were analyzed according to Hardy-Weinberg equilibrium using the x2-test.
RESULTS: The short (S) allele of 5-HTTLPR was significantly more frequent in responders than in nonresponders
(p,0.05). Out of the 69 total PE patients, 41 patients (59%) responded to therapy. There was no significant
difference in the International Index of Erectile Function score at the end of therapy between the responder
and nonresponder groups. The frequencies of the L allele and S allele were 20% and 39%, respectively, in the
responder group (p,0.05).
CONCLUSION:We conclude that premature ejaculation patients with the SS genotype respond well to selective
serotonin reuptake inhibitor therapy. Further studies with large patient groups are necessary to confirm this
conclusion.
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& INTRODUCTION
Premature ejaculation (PE) is the most common sexual
problem among men, affecting up to 30% of all males
worldwide (1). It is mediated mainly through disturbances
in serotonergic neurotransmission and serotonin receptors
in the central nervous system (2). The condition has been
classified as either primary (lifelong), beginning when a
man first becomes capable of functioning sexually, or
secondary (acquired), indicating that the patient previously
experienced an acceptable level of ejaculatory control but
then, for unknown reasons, developed the condition later in
life (3). Primary PE is hypothesized to have a strong
biological component, with a variety of psychological
contributing factors (4). Based on experimental evidence,
lifelong PE has recently been defined by the International
Society for Sexual Medicine (ISSM) as ejaculation that occurs
within approximately one minute of penetration during the
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majority of instances of sexual intercourse, with an inability
to delay ejaculation and associated negative personal
consequences, such as stress and avoidance of sexual
activity (5).
Serotonin (5-hydroxytryptamine, 5-HT) plays an impor-
tant role at the level of the central nervous system in the
complex regulatory mechanisms involved in ejaculation. In
clinical practice, selective serotonin reuptake inhibitor
(SSRI) antidepressants (e.g., paroxetine, fluoxetine and
sertraline) and the tricyclic antidepressant clomipramine
are widely used to treat lifelong PE, suggesting that 5-HT
and SSRIs play roles in the pathophysiology and treatment
of PE. In this group, paroxetine and sertraline are often used
effectively to treat PE, although none of these agents have
been officially recognized as treatments for this condition
(6). SSRIs increase synaptic 5-HT concentrations in the
ejaculation-related areas of the central nervous system by
blocking 5-HT transporters. The serotonin transporter (5-
HTT) plays an important role in the clearance of synaptic 5-
HT, thereby regulating presynaptic and postsynaptic 5-HT
receptor stimulation. Human 5-HTT is encoded by a single
gene (SLC6A4) on chromosome 17q12. A polymorphism in
the transcribed region can be caused by a 44-bp insertion
(‘long allele’ [L]) or deletion (‘short allele’ [S]) (7,8).
In the literature, a variety of findings have been reported
concerning the relationship between 5-HTT polymorphism
and the SSRI response (9-11). Paroxetine is the most
commonly used SSRI for PE treatment. Consequently, in
this study, we evaluated the relationship between the 5-
HTT-linked polymorphic region (5-HTTLPR) and the
paroxetine response in patients with lifelong PE.
& MATERIALS AND METHODS
Patients
In this study, 69 Turkish Caucasian male patients with
primary (lifelong) PE between the ages of 21 and 59 years
were admitted to the Urology Outpatient Department at
our hospital (Istanbul, Turkey) and evaluated. PE was
defined as an intravaginal ejaculation latency time of less
than one minute after vaginal penetration occurring in
more than half of all intromissions (12,13). All patients
experienced primary PE and were either married or in a
regular sexual relationship with a female partner. The
patients with erectile dysfunction (ED) and other sexual
problems, including decreased libido, a history of sexual
abuse, chronic prostatitis and infravesical obstruction, were
excluded from the study, as were those with organic,
neurological and psychiatric disorders. Psychoactive med-
ication users and patients with depression, diabetes and
cancer were also excluded from the study. All patients had
similar lifestyles and education levels (at least high school).
Intravaginal ejaculation latency time (IELT) was measured
using a stopwatch. All patients were treated with 20 mg/d
paroxetine for three months. The patients were scored as
having responded to therapy when a 2-fold or greater
increase in IELT was observed compared with baseline
values after three months (13). The patients were divided
into two groups: 44 (64%) of the patients responded to
paroxetine therapy and 25 (36%) did not respond to
therapy. At the end of treatment, the IELT and
International Index of Erectile Function (IIEF) scores were
compared with baseline values.
DNA isolation and polymerase chain reaction (PCR)
protocols
Venous blood samples (5-10 mL) were drawn from PE
patients and subsequently anti-coagulated with EDTA.
Genomic DNA was isolated from the peripheral blood
samples according to a standard salting-out protocol. The
concentration of the isolated DNA was calculated by
measuring the optical density at 260 nm using a T80 UV/
VIS spectrophotometer (PG Instruments, Earl Shilton,
Leicestershire, UK). The 44-bp insertion/deletion poly-
morphism within the promoter region of the serotonin
transporter (SLC6A4) gene was evaluated using PCR (7).
The 5-HTT-linked polymorphic region (5-HTTLPR) was
amplified to determine the presence of an insertion or
deletion using the primers 59-GGCGTTGCCGCTCTGA-
ATC-39 (forward) and 59-GAGGGACTGAGCTGGACAA-
CCAC-39 (reverse). The PCR reaction was performed in a
total volume of 25 mL that included approximately 100 ng
of DNA, 2.5 mL of 10 6 polymerase buffer, 2.0 mmol L-1
MgCl2, 0.2 mmol L-1 dNTPs, 0.4 mmol L-1 of each primer
and 1 U of Taq polymerase (MBI Fermentas, Hanover, MD,
USA). The PCR program on the PTC-150 Minicycler (MJ
Research, Waltham, USA) thermal cycler included the
following steps: an initial denaturation step at 94 C˚ for four
minutes, followed by 33 cycles of 94 C˚ for 30 s, 60 C˚ for
30 s and 72 C˚ for 45 s, with a final extension step at 72 C˚
for eight minutes. The deletion allele yields a 484-bp
product, whereas the insertion allele a 528-bp product. The
amplification products were electrophoresed on 2% agar-
ose gels at 100 V for 30 minutes. The gel and running
buffer was 16 TBE (0.89 mol L-1 Tris base, 0.89 mol L-1
boric acid, 20 mmol L-1 Na2EDTA). The fragments were
visualized using ethidium bromide under an ultraviolet
transilluminator. All experiments were repeated twice in
completely independent assays and produced almost
identical results.
Ethics
This study was approved by the local hospital ethics
committee on human research. Written informed consent
was obtained from all participants.
Statistics
Genotypic data were obtained using the single nucleotide
polymorphism data management program. The observed
number of genotypes was counted for each single nucleo-
tide polymorphism and the genotypic and allele frequencies
were tabulated automatically. Pearson’s x2 was used to test
for deviation from Hardy-Weinberg equilibrium and to
compare the genotypic and allelic frequencies in the PE and
control groups. P-values ,0.05 were considered statistically
significant.
& RESULTS
A total of 41 (59%) of the 69 PE patients responded to
paroxetine therapy, whereas the remaining 28 (41%) did not
respond to therapy. The short (S) allele of the 5-HTT gene
was significantly more frequent in responders than in
nonresponders (p,0.05). No severe side effects causing
discontinuation secondary to paroxetine were observed
during the treatment period. The frequencies of the allele
L and S were 20% and 39%, respectively, in the responder
group (p,0.05). Among the nonresponders to treatment,
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patients with homozygotic LL genotypes were more
common than those with the SS genotype (Table 1). A
dosage of 20 mg/d paroxetine did not affect the IIEF scores
significantly at the end of 12 weeks (p.0.05) (Table 2).
& DISCUSSION
SSRIs are commonly used drugs for the treatment of PE.
Among the SSRI antagonists, paroxetine is a widely used
agent for the pharmacological treatment of PE. In our
patients, we evaluated long-term (12-week) daily use of
20 mg paroxetine and the relationship between the 5-
HTTLPR polymorphism and a positive response to therapy.
Recent studies have described the genetic basis of
primary premature ejaculation. The current study and
others have suggested that the 5-HTTLPR polymorphism
is positively associated with PE (14-20). Despite this known
association, few studies have examined the relationship
between treatment response to SSRIs and genetic poly-
morphisms (21). Our study will help to clarify the genetic
basis of responsiveness and nonresponsiveness to the
pharmacological treatment of PE with SSRIs.
Safarinejad et al. investigated the influence of 5-HTTLPR
and STin2 polymorphisms on the response to an SSRI
(sertraline) (21). This study was the first to demonstrate a
genetic basis for the response to SSRIs used in the treatment
of PE. In the literature, it was previously suggested that
SSRIs responses are partly under genetic control (9,10). In
these studies, the authors evaluated theinfluence of two
polymorphisms (5-HTTLPR and STin2) on the SSRI treat-
ment outcome in women with depression. It was found that
women with the 5-HTTLPR S allele exhibited a less
favorable response to SSRI treatment. Contrary to this
finding, Lewis et al. could not find evidence supporting an
influence of 5-HTTLPR on outcomes following antidepres-
sant treatment in depressive patients; these authors stated
that it is unlikely that the 5-HTTLPR polymorphism alone
could be clinically useful in predicting responses to
antidepressants in patients with depression (22).
The neurobiology of ejaculation is quite complex and the
serotoninergic (5-HT) system plays a central role. Genetic
polymorphisms located on the SLC6A4 gene encoding the 5-
HT transporter (5-HTT), also referred to as the serotonin
transporter (SERT), a major regulator of serotonergic
neurotransmission, have been linked to the pathogenesis
of PE (15-20,22). 5-HTT is responsible for the clearance of
synaptic 5-HT and thus acts as a regulator of presynaptic
and postsynaptic 5-HT receptor stimulation. The SLC6A4
gene has been cloned and mapped to chromosome 17q11.1-
q12 in humans (7). The 5-HTTLPR and STin2 polymorph-
isms in this gene have been proposed to be responsible for
the observed inter-individual and inter-ethnic variation in
responses to SSRI medication in psychiatric patients, such as
those suffering from depression (9,23,24). Because of the
individual and ethnic differences in the 5-HTTLPR poly-
morphism, positive and negative associations with the L
allele have been reported in some studies (24,25). In general,
studies indicating the relationship between 5-HT gene
polymorphisms and response to SSRIs have focused on
psychiatric disorders rather than ejaculatory dysfunction.
Because the long-term use of antidepressants can cause
serious side effects, treatment responsiveness to these
agents is important. In the literature, only one clinical study
has been performed to examine the relationship between
polymorphisms within the 5-HTT-linked polymorphic
region (5-HTTLPR) or within the second intron of the
SLC6A4 gene (STin2) and the clinical response to SSRI
treatment (22). In this study, Safarinejad et al. treated
patients with sertraline 50 mg daily for two weeks and
subsequently increased the dosage to 100 mg daily for a 12-
week treatment period. Following genetic evaluation, the
authors reported that the responses were significantly better
in patients with the L(A)/L(A) genotype of the 5-HTTLPR
polymorphism than in those with the S allele. The STin2 12/
12 genotype was found more often in patients who
responded to sertraline than in those who did not. In this
study, patients with an L(A)/L(A) genotype were more
likely to respond sufficiently to sertraline (odds ratio, 4.66;
95% CI, 2.48-6.14). The authors concluded that the 5-HTT
genotype contributes in unique ways to variations in the
outcome of PE treatment with SSRIs. In our study, we
performed haplotype analysis for three genotypes of 5-
HTTLPR: LL, LS and SS. We did not examine the second
intron of the SLC6A4 gene (STin2). After treatment with
20 mg/d paroxetine for three months, 41 of 69 PE patients
(64%) responded to therapy. The homozygous LL and SS
genotypes were observed in 28 (20%) and 54 (39%) of the
patients in the responder group, respectively (p,0.05). In
our study, PE patients with the SS (39%) genotype
responded well to SSRI therapy. In Safarinejad’s work, the
LL and SS genotype frequencies were 95.6% and 62.6%,
respectively, in the responder group. Fewer patients were
included in our study compared with their study. In our
work, we carefully selected the patient group and excluded
patients who presented neurological or psychiatric dis-
orders. Inter-individual and inter-ethnic differences may be
Table 1 - 5-HTTLPR polymorphisms and IELT scores after
paroxetine treatment.
Paroxetine response (+) Paroxetine response (-)
n, % 41, (59) n, % 28, (41)
5-HTTLPR Genotype n n
LL 6 10
LS 16 12
SS 19 6
Allele
L 28 (20) 32 (23)
S 54 (39) 24 (17)
L: long allele; S: short allele; n: number of patients; 5-HTTLPR: serotonin
transporter-linked polymorphic region; IELT: intravaginal ejaculation
latency time
- A total of 41 (59%) of the 69 PE patients responded and 28 (41%) did not
respond to paroxetine therapy. The short (S) allele of 5-HTTLPR was
significantly more frequent among responder PE patients than among
controls (p,0.05). The frequencies of the allele L and S were 20% and
39%, respectively, in the responder group (p,0.05).
Table 2 - IIEF scores at baseline and at the 3rd month after
initiating paroxetine therapy.
IIEF Baseline 3
rd month
Mean SD Mean SD p
Paroxetine 23.09 2.64 23.32 2.5 0.7
IIEF: International Index of Erectile Function; SD: standard deviation
-Paroxetine (20 mg/d) did not affect IIEF scores significantly at the end of
12 weeks (p.0.05).
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responsible for the differences in L and S allele frequencies
in the SSRI responder group between our study and that of
Safarinejad.
Our findings suggest a positive association between
dominant SS allele polymorphisms of 5-HTTLPR and a
response to SSRIs. Similar to a study conducted by
Safarinejad et al., our study has potentially improved our
understanding of the pathophysiology of premature ejacu-
lation while also predicting the response to treatment.
Further studies, including studies evaluating various ethnic
and socioeconomic groups, are needed to clarify the genetic
basis of responsiveness and nonresponsiveness to the
pharmacological treatment of PE with SSRIs.
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